Account Bag 0

PRODUCT PROFILE

ADINA PT-141 (Bremelanotide) product vial

PT-141 (Bremelanotide)

£24.99

PT-141 (Bremelanotide) is melanocortin receptor agonist; generic medicine name bremelanotide. Researchers examine it in relation to central melanocortin signalling involved in sexual desire and arousal.

Why it is distinct

A centrally acting melanocortin agonist, mechanistically separate from reproductive-axis peptides such as kisspeptin.

  • Evidence stageEstablished
  • AvailabilityAvailable · 20 in stock
  • Batch recordPublished after verification
  • DispatchConfirmed at checkout

20 in stock

SKU: ADINA-END-PT-141-10MG Category: Tags: , ,

PRODUCT INFORMATION

Clear first. Detailed when needed.

What this material is+

PT-141 (Bremelanotide) is melanocortin receptor agonist; generic medicine name bremelanotide. Researchers examine it in relation to central melanocortin signalling involved in sexual desire and arousal.

Research focus+

Researchers study central sexual-response signalling rather than blood flow alone. An authorised version exists for a specific medical use, but this research listing is not that authorised product.

How the mechanism differs+

Acts principally through central melanocortin receptors rather than nitric-oxide vasodilation or sex-hormone replacement.

Evidence and limitations+

An authorised prescription medicine in the US for a defined indication in premenopausal women; status differs by jurisdiction.

Testing and batch documentation+

No live certificate is shown for this staging item. ADINA will only publish a batch document after the product identifier, test method and result have been checked.

RESEARCH PROFILE

Understand the distinction.

Molecular role

Melanocortin receptor agonist; generic medicine name bremelanotide

Research focus

Researchers study central sexual-response signalling rather than blood flow alone. An authorised version exists for a specific medical use, but this research listing is not that authorised product.

How it works

Acts principally through central melanocortin receptors rather than nitric-oxide vasodilation or sex-hormone replacement.

Key differentiator

A centrally acting melanocortin agonist, mechanistically separate from reproductive-axis peptides such as kisspeptin.

Evidence context

An authorised prescription medicine in the US for a defined indication in premenopausal women; status differs by jurisdiction.

Educational research context only. This information is not dosage, administration or personal-use guidance.

CONTINUE EXPLORING

Related research perspectives.

Selected for useful comparison across neighbouring or contrasting research areas—not as combined-use guidance.